A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum

NCT ID: NCT05514782

Last Updated: 2022-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-15

Study Completion Date

2021-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This double-blind, randomized, placebo-controlled, single-center clinical trial was conducted to assess the efficacy and tolerance of an anti-aging daily serum to improve moderate overall photodamage and skin fatigue after 12-weeks of twice-daily used when compared to a placebo-serum (vehicle control). A total of 62 subjects, 34-60 years of age completed study participation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This double-blind, randomized, placebo-controlled, single-center clinical trial was conducted to assess the efficacy and tolerance of an anti-aging daily serum (Cell 1) to improve moderate overall photodamage and skin fatigue of aging skin after 12-weeks days of twice-daily use when compared to the efficacy of a combination of a placebo-control (Cell 2). Skin fatigue was characterized by dehydrated skin with a lack of firmness (visual) and a dull appearance on the global face.

Efficacy and tolerability were assessed through clinical grading at baseline, week 4, week 8, and week 12. Efficacy evaluation on fine lines and wrinkles in the crow's feet area; overall eye appearance on the periocular area; and smoothness (tactile), firmness (visual), radiance, and overall photodamage on the global face were performed at baseline and post-baseline by a clinical grader, a board-certified dermatologist. Furthermore, blinded photo-grading at baseline and week 12 were performed by two board certified dermatologists.

Self-assessment questionnaires, Antera 3D image, Ultrasound Imaging, and VISIA photography were completed at baseline and post-baseline timepoints. Furthermore, 10 randomized subjects, a subset of the study (five in Cell 1 and five in Cell 2) had 2 mm punch skin biopsies collected from the lateral, pre-auricular at baseline and week 12.

A total of 62 subjects completed study participation (31 in Cell 1 and 31 in Cell 2).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Photoaging Wrinkle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double-blinded, placebo-controlled, single-center
Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators
Randomization occurred by assignment to either Cell 1 or Cell 2 using a randomization list, prepared by KGL Skin prior to the start of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anti-Aging Daily Serum

Daily serum composed of a patent-pending botanical extract, bioavailable peptide, antioxidants, postbiotic(s), short term and long-term moisturizers. New product in development.

Group Type ACTIVE_COMPARATOR

Cleansing Lotion

Intervention Type OTHER

Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).

Facial Moisturizer

Intervention Type OTHER

Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.

Sunscreen SPF 40+

Intervention Type OTHER

Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.

Per FDA this intervention is an Over the counter

Placebo-Control

Vehicle control of the anti-aging daily serum.

Group Type PLACEBO_COMPARATOR

Cleansing Lotion

Intervention Type OTHER

Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).

Facial Moisturizer

Intervention Type OTHER

Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.

Sunscreen SPF 40+

Intervention Type OTHER

Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.

Per FDA this intervention is an Over the counter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cleansing Lotion

Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).

Intervention Type OTHER

Facial Moisturizer

Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.

Intervention Type OTHER

Sunscreen SPF 40+

Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.

Per FDA this intervention is an Over the counter

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Revision Skincare® Cleansing Lotion Goodier Cosmetics Facial Moisturizer Aveeno Positively Mineral Sensitive Skin SPF 40+)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female 30 to 60 years of age
* Fitzpatrick skin type I -IV
* Moderate overall photodamage of the skin
* Moderate lack of firmness (visual) of the skin
* Moderate dull appearance of the skin
* Subjects must be willing to withhold all facial treatments during the course of the study and have not undergone a treatment within the last 6 months
* Subject must be willing to provide verbal understanding and written informed consent

Exclusion Criteria

* Diagnosed with known allergies to facial skincare products
* Nursing, pregnant, or planning to become during the duration of the study
* History of skin cancer within the past 5 years
* Having used oral isotretinoin within the last 12 months
* Having used prescription-strength skin-lightening products within the last 3 months
* Having used any anti-wrinkle, skin-lightening, or other product or topical or systemic medication known to affect skin aging or dyschromia within the last 4 weeks
* Having a health condition and/or pre-existing or dermatologic disorder that, in the Investigator's opinion, may interfere with the outcome of the study
* Having observable sunburn, suntan, scars, excessive facial hair, or other dermal conditions on the face that, in the Investigator's opinion, may influence test results
* Having a history of immunosuppression/immune deficiency disorders, or currently using oral or systemic immunosuppressive medications and biologics, and/or undergoing radiation or chemotherapy
* Using or having regularly used systemic or topical corticosteroids within the past 4 weeks
* Having started a long-term medication within the last 2 months
Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KGL, Inc.

OTHER

Sponsor Role collaborator

Revision Skincare

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KGL Skin Study Center

West Chester, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8602

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Skin Care Regimen for Improving Photoaging Signs on the Face
NCT06603857 NOT_YET_RECRUITING PHASE2/PHASE3